UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
UroGen Pharma's price to sales ratio was 6.8× on Nov 11, 2026, against 14.0× a year earlier. Over the last 5 years it ranged from 2.1× to 14.0×, with a median of 5.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.8× | −4.6 |
| 2025 | Dec 31, 2025 | 11.4× | +6.3 |
| 2024 | Dec 31, 2024 | 5.0× | −3.2 |
| 2023 | Dec 29, 2023 | 8.2× | +4.9 |
| 2022 | Dec 30, 2022 | 3.3× | −2.1 |
| 2021 | Dec 31, 2021 | 5.3× | −453.0 |
| 2019 | Jan 31, 2019 | 458.4× | −18.2 |
| 2018 | Dec 31, 2018 | 476.5× | +471.6 |
| 2017 | Dec 29, 2017 | 4.9× | – |
See a number that looks wrong?